ZN-d5 + ZN-c3

ZN-d5 + ZN-c3 is a combination therapy consisting of two oral small molecule inhibitors being investigated for the treatment of acute myeloid leukemia (AML). ZN-d5 is a selective BCL-2 (B-cell lymphoma 2) inhibitor, designed to induce apoptosis in cancer cells by blocking the anti-apoptotic BCL-2 protein. ZN-c3 is an oral inhibitor of the cell cycle checkpoint kinase WEE1, which induces tumor cell apoptosis by disrupting cell cycle regulation. Preclinical and early clinical studies have shown that inhibition of BCL-2 and WEE1 together produces additive or synergistic anti-tumor effects in AML models. This combination is primarily developed by Zentalis Pharmaceuticals for hematologic malignancies such as relapsed/refractory AML[2][3][7][8].